Mounjaro and the Implant: Does Tirzepatide Affect Your Contraception?

The contraceptive implant delivers progestogen subcutaneously into the bloodstream, bypassing the gut entirely — so Mounjaro's effect on gastric emptying does not reduce its contraceptive action.
Oral contraceptive pills are a different matter: NHS guidance recommends adding a non-oral method (such as condoms) for the first four weeks of Mounjaro and for four weeks after each dose increase.
Current UK guidance does not identify a specific interaction between tirzepatide and the implant; always confirm your contraceptive method with your prescriber at consultation.
If you are thinking about trying to conceive, stopping Mounjaro in advance and completing a wash-out period is recommended before conception — discuss timing with your prescriber.

If you use a hormonal implant and are considering Mounjaro for weight management, the reassuring answer is that the implant is not expected to be affected by tirzepatide. Unlike oral contraceptives, the implant releases progestogen directly into the bloodstream rather than through the gut, so the fact that Mounjaro slows gastric emptying is not relevant to how well it works. That said, the full picture involves a few practical points worth understanding before you start treatment, and a prescriber will always discuss your contraception at consultation. Mounjaro is a prescription-only medicine requiring a clinical assessment before it can be supplied.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How to think through this decision before your consultation

Why the implant works differently from the pill on Mounjaro

The core concern with Mounjaro and hormonal contraception centres on absorption. Tirzepatide slows the rate at which the stomach empties, which can reduce how quickly and completely oral medicines (including the combined or progestogen-only pill) are absorbed. That is why NHS guidance on Mounjaro and hormonal contraception singles out oral contraceptives specifically, advising that a non-oral backup method is used for the first four weeks of treatment and for four weeks after any dose increase.

The implant sidesteps this mechanism completely. It is a small flexible rod inserted under the skin of the upper arm, releasing a steady low level of progestogen directly into your bloodstream. There is no gut absorption step. Mounjaro cannot interrupt a process that does not happen. On that basis, the implant is considered unaffected by tirzepatide under current UK clinical guidance.

This distinction matters practically. If you switched to the pill before starting Mounjaro, the pill-specific precaution would apply to you. If you keep the implant, it does not. Worth knowing before you make any contraceptive changes.

What the guidance actually says, and where the gaps are

The NHS England guidance on weight-management injections is explicit that women using oral contraceptives should add a barrier method for the first four weeks of Mounjaro and after each dose step up. It does not flag the same requirement for non-oral hormonal methods, including the implant, the patch, the hormonal coil or injectable contraceptives.

The Mounjaro SmPC (the authoritative prescribing document) notes the gastric-emptying effect on co-administered oral medicines and specifically names oral contraceptives as requiring backup. The implant is not listed as a concern, and if you are curious whether tirzepatide acts as a stimulant or works through some other mechanism, that is covered separately. You can read the full prescribing information via the eMC, which holds the Mounjaro Summary of Product Characteristics.

One honest caveat: the long-term effects of significant weight loss on hormonal levels and contraceptive effectiveness are still being studied across all methods. This is not a Mounjaro-specific concern (rapid body composition changes can affect hormone binding and metabolism) but it is a reason to keep your GP and prescriber informed about your progress rather than treating the question as settled once and done.

The decision you are actually making

Most people reading this are weighing up whether they need to do anything about their contraception before starting Mounjaro. The straightforward answer is: if your only hormonal contraceptive is the implant, current guidance does not require you to add a backup method. That is meaningfully different from the position for pill users.

If you use the pill alongside the implant, the pill precaution applies to you. If you are thinking about changing your contraception (moving from the implant to the pill, say, because your implant is due for replacement) timing that change relative to starting Mounjaro is worth discussing with whoever manages your contraception as well as your Mounjaro prescriber.

Mounjaro treatment is reviewed before every repeat at nume. You can see what that process involves on our Mounjaro treatment plan page, and our clinical team's approach to situations like this is set out on our clinical team profile. A quick look at what Mounjaro costs privately is also useful background if you are still deciding whether to proceed.

Pregnancy, trying to conceive, and timing your stop date

Mounjaro is not recommended during pregnancy, while breastfeeding, or in the period when you are actively trying to conceive. The MHRA and SmPC guidance is that effective contraception should be used throughout treatment and for a wash-out period afterwards, your prescriber will advise on the specific timeframe at consultation, because it varies based on your dosing history.

If you are approaching the end of your implant's three-year lifespan and you are thinking about trying for a baby, that timing conversation becomes especially important. Do not stop your implant and begin trying to conceive without first speaking to your prescriber about when to stop Mounjaro. The wash-out period exists for a reason, and planning it properly is straightforward when you raise it early.

If any of this raises questions specific to your situation, speaking to our prescribers is the right next step. Consultations at nume are free, reviewed the same day by a named clinician, and there is no obligation to proceed. For broader context on how Mounjaro works as a treatment, the Mounjaro overview is a good place to start.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions